Nanoparticles capable of delivering drugs to specifically targeted cancer cells have been created by a group of researchers from China.
The multifunctional 'smart' gold nanoshells could lead to more effective cancer treatments by overcoming a major limitation of modern chemotherapy techniques—the ability to target cancer cells specifically and leave healthy cells untouched.
Small peptides situated on the surface of the nanoshells are the key to the improved targeting ability, guiding the nanoshells to specific cancer cells and attaching to markers on the surface of the cells. The acidic environment of the cancer cells then triggers the offloading of the anticancer drugs.
The specific nanostructure of the gold nanoshells could also allow near-infrared light to be absorbed and converted into heat, opening up the possibility of using the nanoshells in targeted hyperthermia treatment—another form of cancer treatment whereby cancer cells are exposed to slightly higher temperatures than usual to destroy them.
The first results of the nanoshells' performance have been published today, 14 February, in IOP Publishing's journal Biomedical Materials.
The researchers, from East China Normal University and Tongji University, used the gold nanoshells as a building block to which they attached the commonly used anticancer drug Doxorubicin (DOX) and a specific peptide known as A54.
The gold nanoshells had diameters of around 200 nanometres—more than 50 times smaller than a red blood cell.
When tested on human liver cancer cells, the uptake of the nanoshells that had the A45 peptide was three times greater than the uptake of the control nanoshells without the peptide. There was also a significantly reduced uptake of both types of nanoshell by normal healthy cells.
The cancer cells were also treated with the gold nanoshells in a heated water bath and were shown to deliver a notable therapeutic effect compared to just the chemotherapy, demonstrating the potential of the hyperthermia treatment.
Lead author of the study Dr Shunying Liu, from East China Normal University, said: "The therapeutic activity of most anticancer drugs is limited by their systematic toxicity to proliferating cells, including some normal cells. Overcoming this problem remains a great challenge for chemotherapy."
"In our study we placed a targeting peptide on the nanoshells, which have been demonstrated to be specific to live cancer cells, improving the targeting ability and drug delivery of the gold nanoshells.
"The next step of our research is to test the 'smart' gold nanoshells in vivo on a liver cancer mouse model. We will also examine how the size of the nanoshells changes their efficacy and how efficient the nanoshells are at converting near-infrared light into heat."
From Friday 14 February this paper can be downloaded from http://iopscience.iop.org/1748-605X/9/2/025012
Notes to Editors
Contact
1. For further information, a full draft of the journal paper or contact with one of the researchers, contact IOP Press Officer, Michael Bishop:
Tel: 0117 930 1032
E-mail: michael.bishop@iop.org
For more information on how to use the embargoed material above, please refer to our embargo policy.
IOP Publishing Journalist Area
2. The IOP Publishing Journalist Area gives journalists access to embargoed press releases, advanced copies of papers, supplementary images and videos. In addition to this, a weekly news digest is uploaded into the Journalist Area every Friday, highlighting a selection of newsworthy papers set to be published in the following week.
Login details also give free access to IOPscience, IOP Publishing's journal platform.
To apply for a free subscription to this service, please email Michael Bishop, IOP Press Officer, michael.bishop@iop.org, with your name, organisation, address and a preferred username.
"'Smart' gold nanoshells for combined cancer chemotherapy and hyperthermia"
3. The published version of the paper "'Smart' gold nanoshells for combined cancer therapy and hyperthermia" (2014 Biomed. Mater. 9 025012) will be freely available online from Friday 14 February. It will be available at http://iopscience.iop.org/1748-605X/9/2/025012.
Biomedical Materials
4. Biomedical Materials (BMM) publishes original research findings that contribute to our knowledge about the composition, properties, and performance of materials for tissue engineering and regenerative medicine.
IOP Publishing
5. IOP Publishing provides a range of journals, magazines, websites and services that enable researchers and research organisations to reach the widest possible audience for their research.
We combine the culture of a learned society with global reach and highly efficient and effective publishing systems and processes. With offices in the UK, US, Germany, China and Japan, and staff in many other locations including Mexico and Russia, we serve researchers in the physical and related sciences in all parts of the world.
IOP Publishing is a wholly owned subsidiary of the Institute of Physics. The Institute is a leading scientific society promoting physics and bringing physicists together for the benefit of all. Any profits generated by IOP Publishing are used by the Institute to support science and scientists in both the developed and developing world. Go to ioppublishing.org.
Access to Research
6. Access to Research is an initiative through which the UK public can gain free, walk-in access to a wide range of academic articles and research at their local library. This article is freely available through this initiative. For more information, go to http://www.accesstoresearch.org.uk
The Institute of Physics
7. The Institute of Physics is a leading scientific society. We are a charitable organisation with a worldwide membership of more than 50,000, working together to advance physics education, research and application. We engage with policymakers and the general public to develop awareness and understanding of the value of physics and, through IOP Publishing, we are world leaders in professional scientific communications. Go to http://www.iop.org
Journal
Biomedical Materials